Evidence map›Paper›PMID 28643124›Full record

ReviewDer Pathologe2017

[Solid pediatric tumors : A brief survey of the rarity cabinet].

B Gürtl-Lackner, D Gisselsson-Nord, G Vujanic

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Pathologe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

B Gürtl-LacknerInstitut für Pathologie, Labmedicin Skåne, Sölvegatan 25, Lund, Schweden. Barbara.GurtlLackner@skane.se.
D Gisselsson-NordInstitut für Pathologie, Labmedicin Skåne, Sölvegatan 25, Lund, Schweden.
G VujanicAbteilung für Zelluläre Pathologie, Universitätsklinikum Wales, Universität Cardiff, Cardiff, Großbritannien.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid tumors in childhood are extremely rare entities, which are usually treated in specialized centers. Diagnosis and therapy are carried out according to a joint European protocol, whereby the pathological evaluation and therapy are carried out according to international guidelines. For the correct diagnosis and/or therapy of most tumors, analysis of specific genetic changes is mandatory; therefore, tumors have to be adequately sampled for parallel genetic analysis during the pathological work-up. A second opinion reference of the histopathological assessment is part of the international guidelines. Neuroblastomas, congenital mesoblastic nephromas and rhabdoid tumors are examples of solid tumors in childhood that are not restricted to one organ and occur exclusively during childhood.

Indexed as

Rare DiseasesChildChild, PreschoolFemaleGuideline AdherenceHumansInfantInfant, NewbornKidney NeoplasmsNeoplasmsNephroma, MesoblasticNeuroblastomaPregnancyProto-Oncogene Proteins c-mycReferral and ConsultationRhabdoid TumorMYC protein, humanProto-Oncogene Proteins c-mycSMARCB1 ProteinSMARCB1 protein, humanCongenital mesoblastic nephromaINI1/SMARCB1MYC-NNeuroblastomaRhabdoid tumors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.